271 related articles for article (PubMed ID: 17395091)
1. Research & market strategy: how choice of drug discovery approach can affect market position.
Sams-Dodd F
Drug Discov Today; 2007 Apr; 12(7-8):314-8. PubMed ID: 17395091
[TBL] [Abstract][Full Text] [Related]
2. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
Betz UA
Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
[TBL] [Abstract][Full Text] [Related]
3. Goodbye Columbus! New NRDOs forego discovery.
Thiel KA
Nat Biotechnol; 2004 Sep; 22(9):1087-92. PubMed ID: 15340473
[No Abstract] [Full Text] [Related]
4. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
5. Does brand differentiate pharmaceuticals?
Bednarik J
Neuro Endocrinol Lett; 2005 Dec; 26(6):635-52. PubMed ID: 16380705
[TBL] [Abstract][Full Text] [Related]
6. Jonathan K. C. Knowles discusses the impact of pharmacogenomics on market segmentation.
Knowles JK
Nat Rev Drug Discov; 2004 Oct; 3(10):822. PubMed ID: 15497246
[No Abstract] [Full Text] [Related]
7. The long and winding road.
Nat Rev Drug Discov; 2005 Jun; 4(6):443. PubMed ID: 15959946
[No Abstract] [Full Text] [Related]
8. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
Micklus A; Muntner S
Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
[No Abstract] [Full Text] [Related]
9. Defensive marketing: how a strong incumbent can protect its position.
Roberts JH
Harv Bus Rev; 2005 Nov; 83(11):150-2, 154, 156-7 passim. PubMed ID: 16299967
[TBL] [Abstract][Full Text] [Related]
10. No immediate pain relief for the pharmaceutical industry.
Ahlborn H; Henderson S; Davies N
Curr Opin Drug Discov Devel; 2005 May; 8(3):384-91. PubMed ID: 15892254
[TBL] [Abstract][Full Text] [Related]
11. To measure is to know: an approach to CADD performance metrics.
Loughney D; Claus BL; Johnson SR
Drug Discov Today; 2011 Jul; 16(13-14):548-54. PubMed ID: 21605697
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
13. Compound scale-up at the discovery-development interface.
Nikitenko AA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
[TBL] [Abstract][Full Text] [Related]
14. The promise of a virtual lab in drug discovery.
Rauwerda H; Roos M; Hertzberger BO; Breit TM
Drug Discov Today; 2006 Mar; 11(5-6):228-36. PubMed ID: 16580600
[TBL] [Abstract][Full Text] [Related]
15. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460
[TBL] [Abstract][Full Text] [Related]
16. Arguments against precompetitive collaboration.
Vargas G; Boutouyrie B; Ostrowitzki S; Santarelli L
Clin Pharmacol Ther; 2010 May; 87(5):527-9. PubMed ID: 20407456
[No Abstract] [Full Text] [Related]
17. Cytomics and drug discovery.
Van Osta P; Ver Donck K; Bols L; Geysen J
Cytometry A; 2006 Mar; 69(3):117-8. PubMed ID: 16496374
[TBL] [Abstract][Full Text] [Related]
18. Outsourcing lead optimization: constant change is here to stay.
Clark DE
Drug Discov Today; 2007 Jan; 12(1-2):62-70. PubMed ID: 17198974
[TBL] [Abstract][Full Text] [Related]
19. Missed opportunities in pharma?
Owens J
Nat Rev Drug Discov; 2004 Oct; 3(10):893. PubMed ID: 15497248
[No Abstract] [Full Text] [Related]
20. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED; Van Dam J; Szalma S
Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
[No Abstract] [Full Text] [Related]
[Next] [New Search]
